F-12682

F-12682
Clinical data
Other namesF12682; F-12318; F12318
Routes of
administration		Unknown[1]
Drug classSerotonin 5-HT1B and 5-HT1D receptor inverse agonist
ATC code
  • None
Identifiers
  • N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-(2-phenylethyl)piperazine-1-carboxamide
PubChem CID
ChemSpider
Chemical and physical data
FormulaC25H35N5O2
Molar mass437.588 g·mol−1
3D model (JSmol)
  • CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)CCC4=CC=CC=C4)OC
  • InChI=1S/C25H35N5O2/c1-27-12-16-29(17-13-27)23-20-22(8-9-24(23)32-2)26-25(31)30-18-14-28(15-19-30)11-10-21-6-4-3-5-7-21/h3-9,20H,10-19H2,1-2H3,(H,26,31)
  • Key:SDXUUOUVEULXIO-UHFFFAOYSA-N

F-12682 is a serotonin 5-HT1B and 5-HT1D receptor inverse agonist which was under development for the treatment of major depressive disorder but was never marketed.[1][2][3] Its route of administration is unknown.[1] The drug was under development by Laboratoires Pierre Fabre in France and was first described in the literature by 1998.[1][2][3] It reached the preclinical research or discovery stage of development prior to the discontinuation of its development in 1999.[1][2][3]

See also

References

  1. ^ a b c d e "F 12682". AdisInsight. 12 May 1999. Retrieved 5 June 2026.
  2. ^ a b c "Delving into the Latest Updates on F-12682 with Synapse". Synapse. 16 May 2026. Retrieved 5 June 2026.
  3. ^ a b c "F-12682: new 5-HT1B/1D receptor inverse agonist for depression". BioWorld. 15 September 1998. Retrieved 5 June 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.